ReviewJournal of pharmaceutical analysis2023
Ginsenoside Rc: A potential intervention agent for metabolic syndrome.
Review in Journal of pharmaceutical analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Ginsenoside Rc exerts protective effects against cerebral ischemia‒reperfusion injury by boosting the Nrf2 pathway through targeted activation of Sirt1.In vitro cellular & developmental biology. Animal · 2026Article
- Keratin 18 functions as a lactyltransferase to trigger necroptosis in diabetic kidney disease by modulating Fas transcription.Experimental & molecular medicine · 2026Article
- Biomimetic hybrid nanocarriers hitchhike neutrophils for targeted ginsenoside Rc delivery to BMSCs: ameliorating postmenopausal osteoporosis via iron homeostasis regulation.Journal of nanobiotechnology · 2026Article
- Research Progress on the Anticancer Effect of Ginsenoside Rh1.Current issues in molecular biology · 2026Review
- The scientific basis of synergy in traditional Chinese medicine: physicochemical, pharmacokinetic, and pharmacodynamic perspectives.Chinese medicine · 2026Review
- Research Progress and Prospects of Saponins in the Treatment of NAFLD: A Narrative Review.Molecules (Basel, Switzerland) · 2025Review
- Review
- Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics.Journal of nanobiotechnology · 2025Review
- Unlocking ginsenosides' therapeutic power with polymer-based delivery systems: current applications and future perspectives.Frontiers in pharmacology · 2025Review
- Effect of Ginseng Supplementation on Exercise Endurance as a Support for Cardiovascular Disease Management: A Systematic Review and Meta-Analysis.Antioxidants (Basel, Switzerland) · 2024Review
- Application of microorganisms in Panax ginseng: cultivation of plants, and biotransformation and bioactivity of key component ginsenosides.Archives of microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ginsenoside Rc, a dammarane-type tetracyclic triterpenoid saponin primarily derived from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.